PROK catalyst calendar

PROKIDNEY CORP.

Upcoming catalysts
2
Cash runway
5.4 months
Cash & investments
$75M
Phase 3 programs
1

PROKIDNEY CORP. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on November 8, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.

Cash runway is approximately 5.4 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 7 concluded trials, 57% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 8, 2026 est. Next quarterly earnings (projected) Earnings —
December 15, 2029 Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease Trial Milestone Phase 3

Track PROK alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PROK in the tracker

Recent history

DateEventTypePhase
August 10, 2026 Quarterly results filed (8-K) Earnings —
May 15, 2026 Quarterly results filed (8-K) Earnings —
March 18, 2026 Quarterly results filed (8-K) Earnings —
February 2, 2026 8-K filed: Reg FD disclosure, Other event Filing —
January 12, 2026 8-K filed: Reg FD disclosure Filing —
November 10, 2025 Quarterly results filed (8-K) Earnings —
October 17, 2025 8-K filed: Material agreement Corporate —
August 12, 2025 Quarterly results filed (8-K) Earnings —
July 15, 2025 8-K filed: Reg FD disclosure, Other event Filing —
July 14, 2025 8-K filed: Material agreement, Other event Corporate —
July 8, 2025 8-K filed: Reg FD disclosure Filing —
July 1, 2025 8-K filed: Reg FD disclosure Filing —
May 30, 2025 8-K filed: Reg FD disclosure Filing —
May 20, 2025 Renal Autologous Cell Therapy (REACT) in Subjects With Type 1 or 2 Diabetes and Chronic Kidney Disease (REGEN-007) Trial Milestone Phase 2
May 12, 2025 Quarterly results filed (8-K) Earnings —
March 19, 2024 A Study of Participants With Chronic Kidney Disease Previously Treated With REACT Trial Milestone Phase 1
December 15, 2023 A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Trial Milestone Phase 2
January 31, 2023 A Study of a Renal Autologous Cell Therapy (REACT) in Patients With Chronic Kidney Disease (CKD) From Congenital Anomalies of the Kidney and Urinary Tract (CAKUT). Trial Milestone Phase 1
November 17, 2022 A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease Trial Milestone Phase 2
May 15, 2017 Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.